Naturally occurring CD4+ T-cell epitope variants act as altered peptide ligands leading to impaired helper T-cell responses in hepatitis C virus infection-Reference-Cited by-同舟云学术

Naturally occurring CD4+ T-cell epitope variants act as altered peptide ligands leading to impaired helper T-cell responses in hepatitis C virus infection

Published:2011-05 Issue:5 Volume:72 Page:379-385
ISSN:0198-8859
Container-title:Human Immunology
language:en
Short-container-title:Human Immunology

Author:

Cusick Matthew F.,Yang Meiying,Gill Joan C.,Eckels David D.

Publisher

Elsevier BV

Subject

General Medicine,Immunology,Immunology and Allergy

Reference35 articles.

1. Ligand recognition by alpha beta T-cell receptors;Davis;Annu Review Immunol,1998

2. Kinetic proofreading in T-cell receptor signal transduction;McKeithan;Proc Natl Acad Sci U S A,1995

3. Altered peptide ligand-induced partial T-cell activation: Molecular mechanisms and role in T-cell biology;Sloan-Lancaster;Annu Rev Immunol,1996

4. Therapeutic vaccination against chronic viral infection: The importance of cooperation between CD4+ and CD8+ T cells;Zajac;Curr Opin Immunol,1998

5. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C;Gerlach;Gastroenterology,1999

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T-Cell Immunity against the Hepatitis C Virus: A Persistent Research Priority in an Era of Highly Effective Therapy;Cold Spring Harbor Perspectives in Medicine;2020-03-23

2. Imprinting and Editing of the Human CD4 T Cell Response to Influenza Virus;Frontiers in Immunology;2019-05-07

3. Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay?;Cells;2019-04-03

4. The antigenic variability of HCV in viral HLA-Ag binding is related to the activation of the host immune response;Scientific Reports;2017-11-14

5. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors;Cancer Immunology, Immunotherapy;2016-02-03